Established in 2015, Beijing Imunopharm Technology Co., Ltd. is devoted to developing innovative gene and cell therapies for curing malignant tumors. Imunopharm has independently developed a new generation of CAR-T technology, which is leading in the field to achieve full-process serum-free production, large-scale gene vector preparation, high production success rate and long-term in vivo persistence of CAR-T cells. As a result, the efficacy and safety of our CAR-T products are greatly improved. Additionally, Imunopharm owns spacious open and clean laboratories, as well as manufacturing facilities that fully meet regulations of China, US and EU, which guarantees one-stop CAR-T production at high quality. Since its establishment, Imunopharm has received three approvals for Investigational New Drug applications.